Key Cohorts

Key Cohorts

The main clinical cohorts that will be used by the Consortium include the LURIC and the COROGENE studies.


The Ludwigshafen Risk and Cardiovascular Health (LURIC) study is an ongoing prospective study of currently > 3800 individuals of German ancestry in whom the cardiovascular and metabolic phenotypes CAD, MI, dyslipidaemia, hypertension, metabolic syndrome and diabetes mellitus have been defined or ruled out using standardised methodologies in all study participants. The database generated currently contains >2200 entries per individual, including inflammatory markers, adhesion molecules, cell surface markers, lipoproteins, biochemical indicators of heart failure and about 1 million single nucleotide polymorphisms (SNPs from Affy 6.0 chip) at genes possibly implicated in coronary heart disease. A 10-year clinical follow-up has recently been conducted.


The Finnish Corogene study has a similar design as the LURIC study and can be directly used to validate biomarker findings. Corogene study consists of 5000 patients assigned to coronary angiogram in Helsinki University Central Hospital. The Corogene biobank consists of fresh plasma and serum samples without any previous freeze thaw cycles that will allow also detailed lipoprotein fraction isolations. The clinical databank contains all needed clinical info as well as mortality and morbidity data for a three year follow-up period.

Other cohorts that are being considered for RiskyCAD include the SPUM-ACS study and the ILLUMINATE trial. SPUM-ACS is an on-going nationwide study in ACS patients is Switzerland with primary outcome measures being major adverse cardiovascular events (MACE) during 12 months follow-up. ILLUMINATE is a trial of 15,067 patients with coronary heart disease (CHD) comparing atorvastatin plus torcetrapib vs atorvastatin plus placebo treatment and looking at MACE as its primary endpoint.